Hydrogen-deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa.
factor IX
factor XI
factor XIa
hemostasis
mass spectrometry
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
03
07
2019
revised:
06
08
2019
accepted:
19
08
2019
pubmed:
14
9
2019
medline:
9
9
2020
entrez:
14
9
2019
Statut:
ppublish
Résumé
Factor XI (FXI) is a zymogen in the coagulation pathway that, once activated, promotes haemostasis by activating factor IX (FIX). Substitution studies using apple domains of the homologous protein prekallikrein have identified that FIX binds to the apple 3 domain of FXI. However, the molecular changes upon activation of FXI or binding of FIX to FXIa have remained largely unresolved. This study aimed to gain more insight in the FXI activation mechanism by identifying the molecular differences between FXI and FXIa, and in the conformational changes in FXIa induced by binding of FIX. Hydrogen-deuterium exchange mass spectrometry was performed on FXI, FXIa, and FXIa in complex with FIX. Both activation and binding to FIX induced conformational changes at the interface between the catalytic domain and the apple domains of FXI(a)-more specifically at the loops connecting the apple domains. Moreover, introduction of FIX uniquely induced a reduction of deuterium uptake in the beginning of the apple 3 domain. We propose that the conformational changes of the catalytic domain upon activation increase the accessibility to the apple 3 domain to enable FIX binding. Moreover, our HDX MS results support the location of the proposed FIX binding site at the beginning of the apple 3 domain and suggest a mediating role in FIX binding for both loops adjacent to the apple 3 domain.
Sections du résumé
BACKGROUND
Factor XI (FXI) is a zymogen in the coagulation pathway that, once activated, promotes haemostasis by activating factor IX (FIX). Substitution studies using apple domains of the homologous protein prekallikrein have identified that FIX binds to the apple 3 domain of FXI. However, the molecular changes upon activation of FXI or binding of FIX to FXIa have remained largely unresolved.
OBJECTIVES
This study aimed to gain more insight in the FXI activation mechanism by identifying the molecular differences between FXI and FXIa, and in the conformational changes in FXIa induced by binding of FIX.
METHODS
Hydrogen-deuterium exchange mass spectrometry was performed on FXI, FXIa, and FXIa in complex with FIX.
RESULTS
Both activation and binding to FIX induced conformational changes at the interface between the catalytic domain and the apple domains of FXI(a)-more specifically at the loops connecting the apple domains. Moreover, introduction of FIX uniquely induced a reduction of deuterium uptake in the beginning of the apple 3 domain.
CONCLUSIONS
We propose that the conformational changes of the catalytic domain upon activation increase the accessibility to the apple 3 domain to enable FIX binding. Moreover, our HDX MS results support the location of the proposed FIX binding site at the beginning of the apple 3 domain and suggest a mediating role in FIX binding for both loops adjacent to the apple 3 domain.
Identifiants
pubmed: 31519061
doi: 10.1111/jth.14632
pmc: PMC6916417
pii: S1538-7836(22)03100-2
doi:
Substances chimiques
Factor IX
9001-28-9
Factor XI
9013-55-2
Factor XIa
EC 3.4.21.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2047-2055Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Références
J Biol Chem. 2005 Oct 28;280(43):36165-75
pubmed: 16085935
N Engl J Med. 2000 Mar 9;342(10):696-701
pubmed: 10706899
Am J Clin Pathol. 2006 Sep;126(3):411-5
pubmed: 16880142
Blood. 2006 Dec 15;108(13):4045-51
pubmed: 16931632
J Thromb Haemost. 2010 Nov;8(11):2349-57
pubmed: 20727068
J Clin Invest. 1997 May 15;99(10):2323-7
pubmed: 9153272
J Thromb Haemost. 2019 May;17(5):759-770
pubmed: 30801944
Haemophilia. 2014 May;20 Suppl 4:71-5
pubmed: 24762279
Biochemistry. 1991 Feb 26;30(8):2056-60
pubmed: 1998667
J Biol Chem. 1996 Nov 15;271(46):29023-8
pubmed: 8910554
Thromb Haemost. 2018 Feb;118(2):340-350
pubmed: 29378358
Chem Soc Rev. 2011 Mar;40(3):1224-34
pubmed: 21173980
Nat Struct Mol Biol. 2006 Jun;13(6):557-8
pubmed: 16699514
Thromb Res. 2018 Jan;161:94-105
pubmed: 29223926
J Biol Chem. 1999 Dec 17;274(51):36373-8
pubmed: 10593931
J Biol Chem. 1991 Apr 25;266(12):7353-8
pubmed: 2019570
Blood. 2013 May 9;121(19):3962-9
pubmed: 23515926
Blood. 2010 Apr 1;115(13):2569-77
pubmed: 20110423
Blood. 1995 Oct 15;86(8):3035-42
pubmed: 7579397
J Biol Chem. 2012 Nov 2;287(45):38200-9
pubmed: 22961984
J Thromb Haemost. 2013 Jul;11(7):1374-84
pubmed: 23617568
Thromb Res. 2014 May;133 Suppl 1:S48-51
pubmed: 24759143
J Biol Chem. 2008 Mar 14;283(11):6696-705
pubmed: 18192270
J Thromb Haemost. 2019 Dec;17(12):2047-2055
pubmed: 31519061